GSK and Genmab receive European approval for Arzerra
GlaxoSmithKline (GSK) and Genmab have received European Commission marketing authorisation for Arzerra as first-line treatment for chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Marketing | Pharmaceuticals | Treanda